MimiVax Receives $1,550,000 New Round

  • Feed Type
  • Date
    8/28/2015
  • Company Name
    MimiVax
  • Mailing Address
    Elm & Carlton Streets MRC Buffalo, NY 14263 USA
  • Company Description
    MimiVax is commercializing intellectual property developed at Roswell Park Cancer Institute (RPCI) through bench to bedside clinical translation. We are developing immunotherapeutic vaccines and targeted therapies for cancer treatment. SurVaxM is our lead drug pipeline agent.
  • Website
    http://www.mimivax.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,550,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy